» Articles » PMID: 8483401

Stability of Time-tradeoff Utilities in Survivors of Myocardial Infarction

Overview
Publisher Sage Publications
Date 1993 Apr 1
PMID 8483401
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

To investigate whether time-tradeoff utilities of survivors of myocardial infarction change over time and whether changes in utilities correlate with changes in functional status, the authors conducted serial interviews using a time tradeoff and three measures of functional status in a cohort of 67 patients who had recently had myocardial infarction. The patients were also asked to rate their overall health on a rating scale and were asked about chest pain, exercise status, and employment status. Each patient was interviewed two to five times over one and a half years. The mean (95% CI) time-tradeoff score for all patients was 0.88 (0.84, 0.93). Over a mean interval of 8.4 months, 28 (42%) patients changed Karnofsky scores, 28 (42%) changed Specific Activity Scale classes, and 11 (16%) changed New York Heart Association classes, with most changes representing improvements in functional status. Scores on the rating scale improved by a mean (95% CI) of 0.06 [(0.03, 0.10); p < 0.002], but scores on the time tradeoff remained stable, with a mean (95% CI) change of 0.03 [(-0.02, 0.08); p = NS]. Changes in time-tradeoff scores did not correlate with changes in Specific Activity Scale classes (Kendall's tau = 0.21), New York Heart Association classes (tau = -0.02), or Karnofsky scores (tau = 0.14); with changes on the verbal rating scale (R = 0.20); with changes in chest pain status (tau = -0.05), exercise status (tau = 0.11), or employment status (tau = 0.11); or with interim hospitalizations (tau = 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Cost-Effectiveness of Colchicine for Recurrent Cardiovascular Events.

Boczar K, Beanlands R, Wells G, Coyle D CJC Open. 2023; 5(5):348-356.

PMID: 37377518 PMC: 10290950. DOI: 10.1016/j.cjco.2023.02.005.


Offering a lifestyle intervention to women of premenopausal age as primary prevention for cardiovascular disease? - assessing its cost-effectiveness.

Gao L, Moodie M Int J Behav Nutr Phys Act. 2022; 19(1):152.

PMID: 36517831 PMC: 9749355. DOI: 10.1186/s12966-022-01384-z.


Cost-Effectiveness of Canakinumab From a Canadian Perspective for Recurrent Cardiovascular Events.

Boczar K, Beanlands R, Wells G, Coyle D CJC Open. 2022; 4(5):441-448.

PMID: 35607490 PMC: 9123368. DOI: 10.1016/j.cjco.2022.01.003.


Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving.

Menut K, Pearlstein S, Conroy P, Roman S, Shen W, Gosnell J Surgery. 2021; 171(1):96-103.

PMID: 34238603 PMC: 9308489. DOI: 10.1016/j.surg.2021.05.052.


Cost-effectiveness of a statewide public health intervention to reduce cardiovascular disease risk.

Smith L, Atherly A, Campbell J, Flattery N, Coronel S, Krantz M BMC Public Health. 2019; 19(1):1234.

PMID: 31492118 PMC: 6728976. DOI: 10.1186/s12889-019-7573-8.